GALT Bathi mangsa ngarep Galectin Therapeutics Inc.

Galectin Therapeutics Inc. (GALT) - logo korporat

Galectin Therapeutics (GALT) is implementing ESG principles and strict bioethical controls into its drug development process. The projected profit reflects expectation dynamics, where the indicator value reaches . The market has already priced in the prolonged wait for the results of Phase 3 trials for cirrhosis. By building a fibrosis therapy ecosystem, Galectin Therapeutics (GALT) aims to become a key link in the treatment of NASH.

Galectin Therapeutics, Inc. (GALT): Bathi sing dikarepake saka 04.07.2022 nganti 17.11.2026

Rincian metrik komprehensif lan analitis Galectin Therapeutics, Inc. (GALT)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:GALT, Galectin Therapeutics, Inc.
Produk merek Galectin Therapeutics Inc.

Galectin Therapeutics (GALT) specializes in developing inhibitors for cirrhosis therapy, anticipating positive FCF following the commercialization of its drugs. The trend in the company's projected profit reflects market expectations for the future monetization of R&D assets, where steady growth of this metric confirms business adaptability, while stagnation in the company's projected profit signals risks of stagnation and low efficiency of capital recovery.